Managing Pulmonary Arterial Hypertension with Sotatercept
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on June 20th, 2025
|
Pulmonary arterial hypertension, if left untreated or poorly controlled, can progress to right ventricular failure and ultimately lead to death. While current therapies can slow disease progression, they have not demonstrated a consistent ability to prevent critical outcomes such as hospitalization, lung transplantation, or mortality. To address this unmet need, a study funded by Merck investigated the use of sotatercept as a potential disease-modifying therapy for PAH.
This phase 3 clinical trial enrolled 172 patients with symptomatic WHO group 1 PAH, with a median age of 55. Approximately half of the participants had idiopathic PAH, while 28% had disease related to connective tissue disorders and 6.4% were affected by drug- or toxin-induced cases. Participants were randomly assigned to receive subcutaneous injections of either a placebo or sotatercept—administered every 21 days at doses ranging from 0.3 to 0.7 mg/kg. Sotatercept functions by inhibiting specific growth factor signaling pathways involved in pulmonary vascular remodeling, a key driver of disease progression.
Over a median follow-up period of approximately seven months, sotatercept was associated with a 76% relative reduction in the combined risk of death, hospitalization, or lung transplantation. Additionally, patients receiving sotatercept demonstrated improvements in biomarkers such as NT-proBNP and showed enhanced physical activity tolerance. However, treatment was also linked to a higher incidence of side effects, including epistaxis and the development of telangiectasia.
This phase 3 clinical trial enrolled 172 patients with symptomatic WHO group 1 PAH, with a median age of 55. Approximately half of the participants had idiopathic PAH, while 28% had disease related to connective tissue disorders and 6.4% were affected by drug- or toxin-induced cases. Participants were randomly assigned to receive subcutaneous injections of either a placebo or sotatercept—administered every 21 days at doses ranging from 0.3 to 0.7 mg/kg. Sotatercept functions by inhibiting specific growth factor signaling pathways involved in pulmonary vascular remodeling, a key driver of disease progression.
Over a median follow-up period of approximately seven months, sotatercept was associated with a 76% relative reduction in the combined risk of death, hospitalization, or lung transplantation. Additionally, patients receiving sotatercept demonstrated improvements in biomarkers such as NT-proBNP and showed enhanced physical activity tolerance. However, treatment was also linked to a higher incidence of side effects, including epistaxis and the development of telangiectasia.